The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Forecasted Rise In Market Size Of The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market During The Forecast Period?
The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market has experienced steady growth in recent years. It is projected to expand from $1.31 billion in 2025 to $1.37 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.6%. In the past, this expansion was attributable to several factors, including the limited availability of targeted therapies, reliance on conventional chemotherapy and radiation therapy, low awareness of her2-positive gastric cancer, restricted access to specialty clinics, and the slow adoption of immunotherapy.
The market for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is projected to experience consistent expansion in the coming years. This market is predicted to reach **$1.64 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.6%.** This anticipated growth during the forecast period stems from factors such as the creation of new antibody-drug conjugates, a rise in clinical investigations for HER2-targeted treatments, improvements in healthcare facilities within developing economies, the advancement of precision medicine and biomarker screening, and an increase in ambulatory surgery centers and specialized oncology clinics. Key trends identified for the upcoming period encompass a greater acceptance of HER2-targeted treatments, enhanced understanding of various gastric cancer subtypes, broader application of immunotherapy and monoclonal antibodies, a rise in tailored treatment strategies, and a stronger emphasis on early diagnosis and screening.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25787&type=smp
What Market Drivers Are Helping Shape The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Expansion?
The increasing adoption of targeted cancer therapy is anticipated to drive growth in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market going forward. This treatment method, also known as personalized medicine, utilizes specific drugs or substances to block cancer growth by concentrating on particular molecules involved in tumor development. The rise in the use of targeted therapy is primarily attributed to advancements in genetic profiling, which allow for more precise treatments tailored to an individual’s unique tumor characteristics, leading to improved effectiveness and fewer side effects. For HER2-positive gastric cancer, targeted therapy functions by directly attacking the HER2 protein, which is overexpressed in these tumors, thereby slowing disease progression and enhancing patient outcomes. For instance, in February 2024, the Food and Drug Administration (FDA) approved 16 new personalized medicines in 2023, including 7 drugs for cancer and 3 for various other diseases and conditions, an increase from 6 in 2022, as reported by the Personalized Medicine Coalition, a US-based professional membership organization. Consequently, the rising adoption of targeted cancer therapy is driving the growth of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market.
How Is Segment Classification Applied In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market covered in this report is segmented –
1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy
2) By Stage: Stage I, Stage II, Stage III, Stage IV
3) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines
2) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, Cytokine-Based Therapies
3) By Radiation Therapy: External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy
4) By Targeted Therapy: HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors
What Trends Are Influencing The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Outlook?
Leading companies within the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market are concentrating on securing approvals for novel treatments, specifically advanced immunotherapy-enhanced combination regimens, which combine immune checkpoint inhibitors with targeted therapy and chemotherapy. This strategy aims to significantly enhance patient outcomes in initial treatment scenarios. The advanced immunotherapy-enhanced combination regimens method works by harnessing the body’s immune system through the suppression of programmed death (PD)-1 or programmed death (PD)-L1 interaction, simultaneously targeting HER2 receptors and employing chemotherapeutic agents, thereby boosting anti-tumor activity and improving survival rates. For instance, in March 2025, Merck & Co., Inc., a US-based biopharmaceutical firm, obtained approval from the U.S. Food and Drug Administration (FDA) for pembrolizumab (Keytruda), used with trastuzumab and chemotherapy, as a primary treatment for adults diagnosed with HER2-positive unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors exhibit programmed death (PD)-L1 expression. This recently approved combination therapy demonstrated a considerable improvement in median progression-free survival and overall survival when compared to conventional treatments. With an elevated overall response rate of 73% and an extended median duration of response, this treatment signifies a transformative approach in addressing advanced HER2-positive gastric cancers.
Which Companies Form The Competitive Landscape Of The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
Major companies operating in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.
Access The Complete Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Report:
Which Regional Market Leads The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=25787&type=smp
Browse Through More Reports Similar to the Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market 2026, By The Business Research Company
Gastric Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report
Gastric Cancer Diagnostic Procedure Market Report 2026
Intestine Cancer Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model